## Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Analysis

This report analyzes the provided data for Sun Pharmaceutical Industries Limited (SUNPHARMA) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Company Profile:**

| Feature          | Description                               |
|-----------------|-------------------------------------------|
| Symbol           | SUNPHARMA                               |
| Company Name     | Sun Pharmaceutical Industries Limited      |
| Industry         | Pharmaceuticals                           |
| Listing Date     | 1995-02-08                               |
| ISIN             | INE044A01036                             |


**2. Key Indicators:**

**2.1 Current Price Analysis:**

| Metric             | Value     |
|----------------------|------------|
| Last Price          | 1,810.00   |
| Change              | -13.30     |
| PChange (%)         | -0.73%     |
| Previous Close      | 1,823.30   |
| Open                | 1,823.30   |
| Close               | 1,808.85   |
| VWAP                | 1,808.38   |
| Week High           | 1,960.35   |
| Week Low            | 1,208.55   |
| Intraday High       | 1,825.95   |
| Intraday Low        | 1,794.10   |
| Sector PE           | 38.74      |
| Symbol PE           | 39.28      |


* The current price shows a slight decrease (-0.73%) compared to the previous close.
* The price is significantly below its week high but above its week low, suggesting some recent volatility.
* Pre-open activity shows buying interest at prices slightly above the previous close.


**2.2 Financial Performance (Last Five Quarters):**

| Quarter Ending    | Income      | Expenditure | Profit After Tax | EPS     |
|--------------------|-------------|--------------|-------------------|---------|
| 30-Sep-2024       | 521,401     | 431,837       | 86,329            | 3.6     |
| 30-Jun-2024       | 458,081     | 432,289       | 23,782            | 1.0     |
| 31-Mar-2024       | 575,802     | 435,624       | 86,760            | 3.6     |
| 31-Dec-2023       | 515,055     | 432,927       | 72,131            | 3.0     |
| 30-Sep-2023       | 520,275     | 429,623       | 88,863            | 3.7     |

* Revenue shows some fluctuation across the quarters.
* Profit after tax shows significant variation, with Q1 FY25 showing a considerable drop.
* EPS also reflects this volatility.


**2.3 Shareholding Analysis:**

| Quarter Ending    | Promoter & Promoter Group (%) | Public (%) |
|--------------------|-----------------------------|------------|
| 30-Sep-2023       | 54.48                        | 45.52      |
| 31-Dec-2023       | 54.48                        | 45.52      |
| 31-Mar-2024       | 54.48                        | 45.52      |
| 30-Jun-2024       | 54.48                        | 45.52      |
| 30-Sep-2024       | 54.48                        | 45.52      |

* Promoter holding remains consistently at 54.48% over the last year.  This indicates stability in ownership.


**2.4 Corporate Action Summary:**

| Ex-Date      | Purpose                               | Amount (Rs) |
|--------------|---------------------------------------|-------------|
| 12-Jul-2024  | Dividend                               | 5           |
| 09-Feb-2024  | Interim Dividend                       | 8.50        |
| 28-Jul-2023  | Dividend                               | 4           |
| 08-Feb-2023  | Interim Dividend                       | 7.50        |
| ...           | ...                                   | ...         |


* The company has a history of consistent dividend payouts, indicating a commitment to shareholder returns.


**2.5 Volatility and Risk:**

* **CM Daily Volatility:** 1.17 (This metric needs context from the source to be fully interpreted.  It likely represents daily price fluctuation.)
* **CM Annual Volatility:** 22.35 (This metric needs context from the source to be fully interpreted. It likely represents annual price fluctuation.)
* Delivery to Traded Quantity: 62.79% (This suggests a relatively high proportion of long-term investors.)

The volatility metrics suggest moderate risk.  Further analysis would be needed to fully assess the risk profile.


**2.6 Key Directors and Contact Info:**

* **Chairperson & MD:** Dilip Shantilal Shanghvi
* **Registrar:** Link Intime India Private Limited (Contact details provided in the data)
* **Company Contact:** secretarial@sunpharma.com


**3. Recent Announcements:**

* Several announcements related to shareholder meetings and newspaper publications.  Specific details require further review of the provided text.


**4. Final Verdict:**

Based solely on the provided data, the recommendation is **Hold**.

**Reasoning:**

* While the company shows a history of dividend payouts and relatively stable promoter holdings, the recent financial performance exhibits significant volatility in profitability and EPS.  The Q1 FY25 results are particularly concerning.  More data is needed to determine if this is a temporary blip or a concerning trend.  The moderate volatility also adds to the uncertainty.

**Conclusion:**

The data presents a mixed picture.  While the company has a history of strong performance and shareholder returns, recent financial results show significant variability.  A more thorough analysis, including a deeper dive into the financial statements and an understanding of the context behind the recent announcements, is needed before a confident buy recommendation can be made.  Therefore, a "Hold" recommendation is appropriate based on the current information.
